Preimplantation genetic testing for monogenic disorders (PGT-M) and preimplantation genetic testing for aneuploidy (PGT-A) are both techniques used during in vitro fertilization (IVF) to assess the genetic health of embryos. PGT-M focuses on screening embryos for single-gene disorders, such as cystic fibrosis, sickle cell anemia, or Huntington's disease, ensuring only embryos free of these conditions are selected. PGT-A, on the other hand, screens for chromosomal abnormalities like trisomy 21 (Down syndrome) or trisomy 18, assessing the number of chromosomes in the embryo. Both tests involve an embryo biopsy followed by genetic analysis. PGT-A helps increase the likelihood of a successful pregnancy by selecting embryos with the correct number of chromosomes. PGT-M is crucial for families with a known history of genetic disorders. Together, these tests enhance IVF outcomes by selecting healthier embryos for implantation.